Rankia España Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
66 / 16.979
#521

Re: Farmas USA

Creo que serán buenos, pero vete tú a saber qué considera bueno el mercado. Mira el palo que se está llevando CELG, con +13% en ventas, pelín por debajo de expectativas y un incremento en beneficios del 57% (!). Pues cotización -6.x%

¿Qué c... espera el mercado? ¿Crecimiento "hasta el infinito y mas allá? lo siento por ellos, tengo buenos amigos dentro y se lo frustrante que resulta hacerlo de PM para que 4 analistos te hundan...

#524

Re: Farmas USA

Jorge A me manda una alerta con esta empresa por si sabes algo de ella parece que los directivos estan comprando, gracias por constestarme ayer.Saludos
OPK - Insider Accumulation
http://finance.yahoo.com/q?s=opk&ql=1
Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico.
Opko Health, Inc. (OPK) -NYSE
4.83 0.05(1.02%) 4:00PM EDT|After Hours: 4.88 0.05 (1.04%) 4:03PM EDT - Nasdaq Real Time Price

Add to Portfolio
Analyst Opinion Get Analyst Opinion for:
Recommendation Summary*
Mean Recommendation (this week): 1.0
Mean Recommendation (last week): 1.0
Change: 0.0
* (Strong Buy) 1.0 - 5.0 (Sell)
Compare to Industry

Price Target Summary
Mean Target: 8.25
Median Target: 8.25
High Target: 8.50
Low Target: 8.00
No. of Brokers: 2
Data provided by Thomson/First Call

PUBLICIDAD

Upgrades & Downgrades History
No Upgrades & Downgrades available for OPK

Recommendation Trends
Current Month Last Month Two Months Ago Three Months Ago
Strong Buy 2 2 2 2
Buy 0 0 0 0
Hold 0 0 0 0
Underperform 0 0 0 0
Sell 0 0 0 0
Data provided by Thomson/First Call

Currency in USD.
Top Insider Trades 4/24/12: OPK, FRAN, PWON And GWRE

#525

Re: Farmas USA

1-Descripción:
Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. It develops a range of solutions, including molecular diagnostics tests, point-of-care tests, and proprietary pharmaceuticals and vaccines to diagnose, treat, and prevent various conditions. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer’s disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; and point-of-care diagnostic test for prostate specific antigen. It is also developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; vaccines using alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate, which has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. In addition, the company offers specialty active pharmaceutical ingredients in Israel; manufactures, markets, sells, and distributes ophthalmic and other pharmaceutical products in Mexico; and markets, sells, and distributes cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones in Chile. OPKO Health, Inc. was founded in 2006 and is based in Miami, Florida.

Vamos, que investigan ellos solos tanto como el NIH, Pfizer y J&J juntos...

2-Datos financieros básicos
Fiscal Year Ends: Dec 31
Most Recent Quarter (mrq): Dec 31, 2011
Profitability
Profit Margin (ttm): -4.59%
Operating Margin (ttm): -82.88%
Management Effectiveness
Return on Assets (ttm): -9.43%
Return on Equity (ttm): -5.51%
Income Statement
Revenue (ttm): 27.98M
Revenue Per Share (ttm): 0.10
Qtrly Revenue Growth (yoy): -52.60%
Gross Profit (ttm): 10.74M
EBITDA (ttm)6: -19.36M
Net Income Avl to Common (ttm): -8.84M
Diluted EPS (ttm): -0.01
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 71.52M
Total Cash Per Share (mrq): 0.24
Total Debt (mrq): 8.76M
Total Debt/Equity (mrq): 4.73
Current Ratio (mrq): 5.30
Book Value Per Share (mrq): 0.55
Cash Flow Statement
Operating Cash Flow (ttm): -18.50M
Levered Free Cash Flow (ttm): 2.18M

3 son claves: ventas 27.98M (para una compañía con un market cap de 1,43B, eso es peanuts), margen bruto -82.88%, EBITDA -19.36M

Si los insiders compran, allá ellos... :D

S2

#526

Re: Farmas USA

Ok.Pasamos pagina,gracias

#527

Re: Farmas USA

Jorge podrias interpretar algo sobre las noticias de ZLCS. Segun seeking alpha hay buenas noticias (hace 1 hora en google finance) y en pre market -4.6. La verdad es que no entiendo nada (la cosa no es que si hy buenas noticias la accion sube?

#528

Re: Farmas USA

Framus, hoy vas a tener ZLCS a cerca de 1$
En pre esta a menos 4%

Guía Básica
Brokers destacados